How to buy Avidity Biosciences stock | $21.94

Avidity Biosciences Inc is a biotechnology business based in the US. Avidity Biosciences shares (RNA) are listed on the NASDAQ and all prices are listed in US Dollars. Avidity Biosciences employs 71 staff and has a trailing 12-month revenue of around 0.00.

Avidity Biosciences stock price (NASDAQ: RNA)

Use our graph to track the performance of RNA stocks over time.

Avidity Biosciences shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$21.94
52-week range	$17.58 - $36.02
50-day moving average	$22.69
200-day moving average	$22.44
Wall St. target price	$46.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.07

Buy Avidity Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Avidity Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avidity Biosciences price performance over time

Historical closes compared with the close of $21.94 from 2021-10-25

1 week (2021-10-19)	2.57%
1 month (2021-09-24)	-6.36%
3 months (2021-07-26)	9.43%
6 months (2021-04-26)	-12.66%

1 year (2020-10-26)	-19.69%
2 years (2019-10-22)	N/A
3 years (2018-10-22)	N/A
5 years (2016-10-22)	N/A

Avidity Biosciences financials

Revenue TTM	$9.2 million
Gross profit TTM	$-30,815,000
Return on assets TTM	-15.09%
Return on equity TTM	-26.2%
Profit margin	0%
Book value	$7.02
Market capitalisation	$1 billion

TTM: trailing 12 months

Shorting Avidity Biosciences shares

There are currently 5.6 million Avidity Biosciences shares held short by investors – that's known as Avidity Biosciences's "short interest". This figure is 3.8% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Avidity Biosciences shares can be evaluated.

Avidity Biosciences's "short interest ratio" (SIR)

Avidity Biosciences's "short interest ratio" (SIR) is the quantity of Avidity Biosciences shares currently shorted divided by the average quantity of Avidity Biosciences shares traded daily (recently around 558970.66402379). Avidity Biosciences's SIR currently stands at 10.09. In other words for every 100,000 Avidity Biosciences shares traded daily on the market, roughly 10090 shares are currently held short.

However Avidity Biosciences's short interest can also be evaluated against the total number of Avidity Biosciences shares, or, against the total number of tradable Avidity Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avidity Biosciences's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Avidity Biosciences shares in existence, roughly 120 shares are currently held short) or 0.1357% of the tradable shares (for every 100,000 tradable Avidity Biosciences shares, roughly 136 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avidity Biosciences.

Find out more about how you can short Avidity Biosciences stock.

Avidity Biosciences share dividends

We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.

Avidity Biosciences overview

Avidity Biosciences, Inc. , a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Frequently asked questions

What percentage of Avidity Biosciences is owned by insiders or institutions?
Currently 9.052% of Avidity Biosciences shares are held by insiders and 85.591% by institutions. How many people work for Avidity Biosciences?
Latest data suggests 71 work at Avidity Biosciences. When does the fiscal year end for Avidity Biosciences?
Avidity Biosciences's fiscal year ends in December. Where is Avidity Biosciences based?
Avidity Biosciences's address is: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037 What is Avidity Biosciences's ISIN number?
Avidity Biosciences's international securities identification number is: US05370A1088 What is Avidity Biosciences's CUSIP number?
Avidity Biosciences's Committee on Uniform Securities Identification Procedures number is: N71546100